**Author details**

the CDC's Advisory Committee on Immunization Practices (ACIP) (http://www.cidrap.umn. edu/news-perspective/2018/02/cdc-vaccine-panel-brings-back-flumist-2018-19-season). It was noted that after the replacement of A/H1N1pdm09 vaccine strain in the quadrivalent LAIV, an immune response was achieved similar to that of highly immunogenic seasonal A/H1N1 viruses circulating before 2009. Therefore, at present, much attention is paid to influenza vaccine strategies that target more broadly reactive antibodies which also apply to potentially

The author is grateful to the postgraduate student of the Institute of Experimental Medicine Ivan Sychev for the editorial changes. The author also expresses thanks to the Microgen and

PATH with the support of which the described studies were performed.

The author confirms that this manuscript content has no conflict of interest.

pandemic vaccine strains.

72 Influenza - Therapeutics and Challenges

**Acknowledgements**

**Conflict of interest**

**Abbreviations**

AGID agar gel immunodiffusion

EID50 fifty percent egg infectious dose

LAIV live attenuated influenza vaccine

MDCK Madin-Darby canine kidney

WHO World Health Organization NI neuraminidase-inhibiting

HI hemagglutination inhibition

CE chick embryos

*ca-* cold-adapted

HP highly pathogenic

MDV master donor virus

MN microneutralization

p.i. post infection

i.n. intranasal

Yulia Desheva1,2\*

\*Address all correspondence to: desheva@mail.ru

1 Virology Department, Federal State Budgetary Scientific Institution, "Institute of Experimental Medicine", Saint Petersburg, Russian Federation

2 Department of Fundamental Problems of Medicine and Medical Technologies, Saint Petersburg State University, Saint Petersburg, Russian Federation
